Titan Pharmaceuticals, Inc.

Thank you for holding and welcome to the Titan Pharmaceuticals third quarter 2020 financial results conference call. Please be advised that this call is being taped at the company's request and will be archived on the company's website starting later today. At this time, I would like to turn the call over to Dr. Mark Rubin, executive chairman of Titan Pharmaceuticals. Please go ahead.

Thank you, Sarah, and as always, thank you to all of you for joining us today. Welcome to the Titan Pharmaceuticals Third Quarter 2020 Conference Call. Before we begin, I want to inform you that we have filed our quarterly report on Form 10-Q with the SEC, and the press release issued earlier today provides a summary of the financial and operational results for the third quarter ending September 30th, 2020, and can also be found on our website at www.titanfarm.com. Joining me on the call today from Titan is Dr. Kate DeVarney, our President and Chief Operating Officer. As you all know, Sineal Bosley has recently made the decision to retire from the company, and we would like to take this opportunity to thank him for his unwavering dedication and many, many, many contributions to Titan over the years. We all wish him the best for his very very well-earned retirement. Moving forward, Kate and I will oversee the company's product development activities. The relevance of our prior operating results is diminished in that Titan has transitioned back from a commercial to a development stage company. So rather than discussing these today, I'd like to draw your attention to the aforementioned filings. And I'll now turn the call to Jennifer Kiernan, who will review the required cautions regarding forward-looking statements. Jennifer?

Thank you, Mark. I want to remind everyone that certain matters that will be discussed today, other than historical information, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product commercialization and development programs, and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business operating results, financial condition, and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to our ability to raise capital, the winding down of U.S. commercial activities related to probufine, the regulatory approval process, the development, testing, production, and marketing of our drug candidates, patent and intellectual property matters, and strategic agreements and relationships. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein, to reflect any change in our expectations or any changes in events, conditions, or circumstances on which any such statement is based, except as required by law. I'll now turn the call back over to you, Mark.